NTRA vs. EXAS, DGX, LH, FTRE, RDNT, UTHR, FMS, UHS, SRPT, and DVA
Should you be buying Natera stock or one of its competitors? The main competitors of Natera include Exact Sciences (EXAS), Quest Diagnostics (DGX), Laboratory Co. of America (LH), Fortrea (FTRE), RadNet (RDNT), United Therapeutics (UTHR), Fresenius Medical Care (FMS), Universal Health Services (UHS), Sarepta Therapeutics (SRPT), and DaVita (DVA). These companies are all part of the "medical" sector.
Natera (NASDAQ:NTRA) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
In the previous week, Natera had 17 more articles in the media than Exact Sciences. MarketBeat recorded 23 mentions for Natera and 6 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.00 beat Natera's score of 0.32 indicating that Exact Sciences is being referred to more favorably in the news media.
Exact Sciences has higher revenue and earnings than Natera. Exact Sciences is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks.
Exact Sciences has a net margin of -8.17% compared to Natera's net margin of -40.16%. Exact Sciences' return on equity of -6.60% beat Natera's return on equity.
Natera has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
99.9% of Natera shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 9.4% of Natera shares are held by insiders. Comparatively, 1.3% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Natera currently has a consensus price target of $86.40, suggesting a potential downside of 5.74%. Exact Sciences has a consensus price target of $97.44, suggesting a potential upside of 65.57%. Given Exact Sciences' higher probable upside, analysts clearly believe Exact Sciences is more favorable than Natera.
Exact Sciences received 495 more outperform votes than Natera when rated by MarketBeat users. Likewise, 72.40% of users gave Exact Sciences an outperform vote while only 68.59% of users gave Natera an outperform vote.
Summary
Exact Sciences beats Natera on 10 of the 18 factors compared between the two stocks.
Get Natera News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
